Highest development stage: Phase 1 Clinical Trial (NCT04890535)

Development status: Active (as of 2023)

Propensity to select resistant bacteria

Mechanism of Action/Target pathogen: Active against <i>Mycobacterium tuberculosis;</i> inhibits ATP synthase

Additional information: Synthetic compound; analogue of bedaquiline that shows greater <i>in vitro </i>potency